SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.38-9.0%Nov 4 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (10465)2/17/2004 6:14:50 PM
From: Biomaven  Read Replies (2) of 52153
 
Putting on my cost-cutting hat, I note over $7 billion of payments for Prevacid and Nexium. The reality is that neither of these are significantly better than generic Prilosec. (The Nexium "improvement" was largely because they compared the new drug to the label dose of Prilosec (20mg) rather than the more potent 40mg dosage form.)

So I contend we could instantly cut $6 billion out of health care costs without significantly hurting the consumer.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News